Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5700240 | Clinical Oncology | 2009 | 7 Pages |
Abstract
This single-centre study reflects the outcome of unselected consecutively treated non-small cell lung cancer patients. Adjusting for stage, there was no significant difference in survival seen according to regimen. Encouragingly, CHART outcome shows reproducibility with the original CHART paper. Our hypofractionated outcome is similar to that previously reported, but despite this being the UK's most common regimen, 55Â Gy in 20 daily fractions remains unvalidated by phase III trial data.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L.S. Pemberton, O.S. Din, P.M. Fisher, M.Q. Hatton,